CD8A and Alzheimer disease: Histopathological results showed that HLJDD had the effect of reducing AD-like pathological damage, and also found that HLJDD could significantly reduce the proportion of M1 type microglia and A1 type astrocytes, and increase the proportion of M2 type microglia and A2 type astrocytes, and the treatment of HLJDD also suppressed the infiltration of CD4+ and CD8+ T-cells in the brain, and inhibited Aβ deposition and reduced the expression of inflammatory factors in the brain, and alleviated central neuroinflammation.